Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.48 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.48 |
| ▸ | OGA | O60502 | 1/20 | 0.48 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18334115 | 0.85 | OGA (0.58) | ACACBKMT2AMAPTRAB9ATLR9 | |
| SCHEMBL1742769 | 0.84 | HRH3 (0.54) | KMT2AMAPTRAB9ATLR9TLR7 | |
| SCHEMBL1742437 | 0.84 | ATP1A1 (0.43) | ACACBMAPTOGASLC6A7GPR119 | |
| SCHEMBL12159783 | 0.82 | FYN (0.46) | KMT2AMAPTRAB9AOGAFYN | |
| SCHEMBL1742764 | 0.82 | OGA (0.46) | ACACBOGASLC6A7DRD2DRD4 | |
| SCHEMBL1742772 | 0.82 | OGA (0.44) | KMT2AMAPTRAB9AOGASLC6A7 | |
| SCHEMBL1744211 | 0.81 | OGA (0.42) | MAPTOGAALDH1A1KDM4ETSHR | |
| SCHEMBL1743089 | 0.80 | CYP1A2 (0.41) | MAPTOGAFYNALDH1A1KDM4E | |
| SCHEMBL9400910 | 0.79 | TGFBR1 (0.58) | KMT2AALDH1A1KDM4EUSP2CYP1A2 | |
| SCHEMBL9986179 | 0.79 | PTPN11 (0.39) | MAPTOGAFYNALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2233470-B1 | Histamine H3 receptor antagonists | HIGH POINT PHARMACEUTICALS LLC (US) | 2011-12-07 | — | — | EP | claimed |
| EP-2233470-A1 | Histamine H3 receptor antagonists | High Point Pharmaceuticals, LLC (US) | 2010-09-29 | — | — | EP | claimed |
| US-8846677-B2 | Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846677-B2 | Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846677-B2 | Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-8501739-B2 | Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501739-B2 | Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501739-B2 | Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-08-06 | — | — | US | disclosed |
| CN-103110635-A | Histamine H3 receptor antagonist | NOVO NORDISK AS | 2013-05-22 | — | — | CN | disclosed |
| US-20120232078-A1 | Novel Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-09-13 | — | — | US | disclosed |
| US-20120232078-A1 | Novel Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-09-13 | — | — | US | disclosed |
| EP-2386554-A1 | Compounds active at the histamine H3 receptor | High Point Pharmaceuticals, LLC (US) | 2011-11-16 | — | — | EP | disclosed |
| EP-2233470-A1 | Histamine H3 receptor antagonists | High Point Pharmaceuticals, LLC (US) | 2010-09-29 | — | — | EP | disclosed |
| EP-2233470-A1 | Histamine H3 receptor antagonists | High Point Pharmaceuticals, LLC (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20090312309-A1 | Novel Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090312309-A1 | Novel Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090312309-A1 | Novel Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-12-17 | — | — | US | disclosed |
| EP-1902028-A2 | HISTAMINE H3 RECEPTOR ANTAGONISTS | Novo Nordisk A/S (DK) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007003604-A2 | HISTS1MINE H3 RECEPTOR ANTAGONISTS | NOVO NORDISK A/S (DK) | 2007-01-11 | — | — | WO | disclosed |
| WO-2007003604-A2 | HISTS1MINE H3 RECEPTOR ANTAGONISTS | NOVO NORDISK A/S (DK) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232078-A1 | Novel Medicaments | HRH3, HRH4, HRH1 | ACACB 4326/4885KMT2A 1116/4885MAPT 2828/4885 |
| US-20090312309-A1 | Novel Medicaments | HRH3, HRH4, HRH1 | ACACB 4326/4885KMT2A 1116/4885MAPT 2828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.